NCT07664852尚未招募3 期
B-HAPPI: Bipolar Disorder and High-dose Adjunctive Pramipexole in Anhedonic Depression - a Phase III, Double-blind, Randomized Controlled Trial
Daniel Lindqvist1 个研究点 分布在 1 个国家目标入组 126 人开始时间: 2026年9月1日最近更新:
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 126
- 试验地点
- 1
研究概览
简要总结
Among psychiatric disorders, bipolar disorder stands out due to its alarmingly high suicide rates. This condition presents unique management challenges, especially during its depressive phase, which carries the highest risk of suicide. B-HAPPI is an academic randomized controlled trial to evaluate a new medication for bipolar depression. It will investigate the efficacy and safety of pramipexole, a potent dopamine agonist that has demonstrated significant effectiveness in bipolar disorder in preliminary studies, showing large effect sizes.
- Population: 126 patients with bipolar depression
- Intervention: Pramipexole added to ongoing treatment with mood stabilizer, flexible dosing - target dose 2.1 mg/day
- Control: Add-on identical placebo
- Outcomes: Primary outcome is change in anhedonia symptoms between baseline and 6 weeks of intervention. Key secondary outcomes include (for example) general depression symptoms and safety measures.
There will be a 15 weeks open label follow up. If shown to be effective and safe, this intervention could become a key treatment option for bipolar depression, reducing suffering and potentially lowering suicide risk.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •The participant has given their written consent to participate in the trial.
- •For WOCBP, adequate contraception should be used (see section 9.6) and a negative pregnancy test is (u-hCG) required. WOCBP: For the purpose of this protocol, a woman is considered of childbearing potential, i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause.
- •Age ≥18 years ≤80 years.
- •Diagnosis of bipolar disorder type I or II as verified by ICD-
- •Ongoing depressive state according to ICD-11 (at least 2 weeks, maximum 18 months).
- •Significant anhedonia, defined as 3 or 4 points on ≥3 items on the SHAPS self-rating scale
- •Minimum score on the MADRS expert rating scale ≥ 20
- •Ongoing treatment with at least one mood stabilising agent (with sufficient antimanic protection as determined by clinical judgment). If treatment with lithium is ongoing, serum levels must be within the reference range of 0.4-0.
- •The latest concentration measurement should be within one month before treatment initiation. If treatment is ongoing with a mood stabilising anticonvulsant or an antipsychotic, any dose adjustments made within 4 weeks prior to study start must be reported. Mood-stabilising anticonvulsants and antipsychotics must not be newly initiated within 4 weeks prior to study start. If treatment with antidepressants is ongoing the dose must have been stable for at least 4 weeks.
排除标准
- •Pregnancy, breastfeeding or planned pregnancy (if female). See also section 8.6 below for clarification.
- •Meets criteria for a mixed episode according to ICD-
- •High suicide risk according to the overall clinical assessment of the research physician.
- •Ongoing substance abuse (within 6 months).
- •Ongoing psychotic symptoms.
- •Prior diagnosis of schizophrenia or schizoaffective disorder.
- •Clinical presentation is primarily attributable to a personality disorder.
- •Subject to compulsory psychiatric care (LPT).
- •History of, or strong clinical suspicion of, impulse control disorder (including current binge-eating disorder). A diagnosis of ADHD is not, in itself, an exclusion criterion; however, participants will be excluded if the clinical presentation is primarily characterised by impulse control-related symptoms.
- •Diagnosis of intellectual disability, dementia, cognitive impairment, or other conditions (including those related to the depressive disorder itself) that, in the judgment of the study physician, may substantially impair the participant's ability to understand the study and provide informed consent.
- •Diagnosis of renal failure (eGFR <50 ml/min/1.73m2) or severe cardiovascular disease (specifically symptomatic heart failure >Class II New York Heart Association (NYHA)).
- •Recently started psychotherapy (within 6 weeks) or planning to start such treatment during participation in the trial. Psychoeducational treatment, which is standard care at bipolar units, is not an exclusion criterion.
- •Ongoing treatment with ECT, ketamine or rTMS.
- •Other medical conditions, other ongoing interventions or other concomitant drug treatment (see section 7.3) that, in the opinion of the investigators, may affect the evaluability of the trial or conditions that increase trial risk. For example: Parkinson's disease, hepatic insufficiency, ongoing cancer not in remission for more than one year.
- •Known or suspected allergy to any active substance or excipient in the medicinal product included in the trial.
- •Participation in other treatment studies.
- •Other reason, as assessed by the investigator, that prevents the research participant's participation, such as the risk that the research participant is unable to complete the trial (non-compliance).
研究组 & 干预措施
Pramipexole-treated
Experimental
6 weeks of treatment with the dopamine agonist pramipexole adjunctive to a mood stabilizer. Target dose 2.1 mg base/day.
干预措施: Pramipexole (Drug)
结局指标
主要结局
未指定
次要结局
- Systematic registration of adverse events, especially (hypo)mania and impulse control related symptoms: Young Mania Rating Scale (YMRS)(Between baseline visit and week 21)
- Systematic registration of adverse events, especially (hypo)mania and impulse control related symptoms: Modified Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease Rating Scale (M-QUIP-RS)(Between baseline visit and week 21)
- Systematic registration of adverse events, especially (hypo)mania and impulse control related symptoms: Modified Problem Gambling Severity Index (M-PGSI)(Between baseline visit and week 21)
- Systematic registration of adverse events, especially (hypo)mania and impulse control related symptoms: Alcohol Use Disorders Identification Test (AUDIT)(Between baseline visit and week 21)
- Systematic registration of adverse events, especially (hypo)mania and impulse control related symptoms: Drug Use Disorders Identification Test (DUDIT)(Between baseline visit and week 21)
研究者
Daniel Lindqvist
Head of Psychiatry Division and research, Principal Investigator, Senior Consultant
Region Skane
研究点 (1)
Loading locations...
相似试验
尚未招募
不适用
Empagliflozin Adjunctive Therapy in Bipolar DepressionBipolar DisorderInsulin ResistanceNCT07472920University of Sao Paulo20
尚未招募
不适用
TMS for Improving Cognitive Function in Bipolar DisorderNCT07414147First Affiliated Hospital of Zhejiang University88
尚未招募
不适用
Anticipating Depressive and Manic Episodes in Bipolar Disorders Using Vocal BiomarkersNCT07298278Centre Hospitalier St Anne170
进行中（未招募）
不适用
Bipolar Disorder Integrative Staging: Incorporating Biomarkers Into Progression Across StagesBipolar DisorderNCT07343739ASST Fatebenefratelli Sacco126
进行中（未招募）
不适用
Multicenter Clinical Randomized Controlled Trial of Unilateral Biportal Endoscopic Spinal Surgery for Degenerative Grade 1 Spondylolisthesis Complicated With Lumbar Spinal StenosisLumbar Spinal Stenosis (LSS)Degenerative Spondylolisthesis G1NCT07303348Changhai Hospital200